

12. (Amended) ~~A booster immunization~~ The method as claimed in claim 10, ~~in which~~ wherein the vaccine is administered via ~~the deep subcutaneous or intramuscular route~~ injection, preferably via the intramuscular route in the deltoid region, in one dose or in two doses of said vaccine, preferably of 0.5 ml, at least 1 month apart.


REMARKS

The foregoing amendments were made to conform to the claims to U.S. practice and are not believed to narrow the scope. Accompanying this Preliminary Amendment is a redlined version of the amended claims as well as a clean copy.

If there are any questions or comments regarding this Response or application, the Examiner is encouraged to contact the undersigned attorney as indicated below.

Date: May 18, 2001

Respectfully submitted,



Michael S. Greenfield

Registration No. 37,142

Telephone: 312-913-0001
Facsimile: 312-913-0002

McDonnell Boehnen Hulbert & Berghoff
300 South Wacker Drive
Chicago, IL 60606

U.S. National Phase of PCT/FR99/02913

Redlined Version of Claims

1. (Amended) A vaccine comprising:
 - less than 1.2 mg per ml of an aluminum salt, wherein the amount is expressed with respect to the Al^{3+} aluminum atom, and
 - immunogenic antigens ~~originating at least from the of~~ poliovirus, from *Corynebacterium diphtheriae* and ~~from~~ *Clostridium tetani*, and
 - ~~—and wherein the amount of the diphtheria toxoid used as an immunogenic antigen of~~ *Corynebacterium diphtheriae* immunogenic antigen of is between 4-16 Lf per ml.
2. (Amended) The vaccine as claimed in claim 1, ~~characterized in that~~ wherein the amount of diphtheria ~~toxoid~~ immunogenic antigen is about 10 Lf per ml.
3. (Amended) The vaccine as claimed in claim 1 ~~or 2, in which~~ wherein the amount of tetanus ~~toxoid~~ immunogenic antigen is about 20 Lf per ml.
4. (Amended) The vaccine as claimed in ~~any one of claims 1 to 3~~ claim 1, ~~also further~~ comprising at least one antigen ~~chosen~~ selected from the group consisting of *Bordetella pertussis*, hepatitis A and hepatitis B antigens.
9. (Amended) A pharmaceutical kit comprising at least 2 injectable doses of ~~a~~ the vaccine as claimed in ~~one of claims 1 to 4~~ claim 1.
10. (Amended) A method for immunizing a human against at least ~~the~~ poliovirus, *Corynebacterium diphtheriae* and *Clostridium tetani*, the method comprising the

~~administration of a~~ administering to the person a vaccine as claimed in any one of claims 1 to 4 ~~claim 1.~~

11. (Amended) ~~A primary immunization~~ The method as claimed in claim 10, ~~in which~~ wherein the vaccine is administered via ~~the~~ deep subcutaneous or intramuscular ~~route~~ injection, preferably via the intramuscular route in the deltoid region, in 3 doses of said vaccine, preferably at 0.5 ml, the first two doses being administered 1 to 2 months apart, and the third dose being administered 6 to 12 months after the injection of the second dose.
12. (Amended) ~~A booster immunization~~ The method as claimed in claim 10, ~~in which~~ wherein the vaccine is administered via ~~the~~ deep subcutaneous or intramuscular ~~route~~ injection, preferably via the intramuscular route in the deltoid region, in one dose or in two doses of said vaccine, preferably of 0.5 ml, at least 1 month apart.